Scott Got­tlieb has a new board po­si­tion to add to the re­sume — and this one is fo­cused on a fa­vorite sub­ject

Scott Got­tlieb has an­oth­er po­si­tion to add to his lengthy ros­ter of boards and ad­vi­so­ry roles in the wake of his de­par­ture from the helm of the FDA.

He’ll be join­ing the ad­vi­so­ry board of Faster­Cures, a think tank which for­mer junk bond king Michael Milken set up to help dri­ve more drugs to the mar­ket, look­ing to ac­cel­er­ate drug R&D. That’s a sub­ject close to the heart of Got­tlieb, who blazed a trail at the FDA fo­cused on hus­tling up the process. That helped en­dear him to the in­dus­try, mak­ing him one of the most pop­u­lar com­mis­sion­ers in FDA his­to­ry.

It’s al­so like­ly to be a much less con­tro­ver­sial post than his board po­si­tion at Pfiz­er, which stirred crit­i­cism from De­mo­c­ra­t­ic pres­i­den­tial can­di­date Eliz­a­beth War­ren.

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER